BNET Industries
Market Cap:$10.7M
Last Fiscal Year Sales:$756.2K
- Public
- US
Dow Jones Description
Ceragenix is developing next generation therapies and products based on its two platforms of technologies both of which mimic key components of the innate immune system CeraShield and Skin Barrier Repair Technology (BRT). Our goal is to become a market leader in developing novel and high-impact therapies and medical products for selected markets in infectious disease and dermatology. The Company seeks to enjoy early revenue opportunities from its first FDA cleared skin Barrier Repair Therapy product, EpiCeram , and will use this cash flow to focus on development of our CeraShield antimicrobial technology for medical devices which is designed to reduce the morbidity, mortality and healthcare costs associated with hospital acquired infections associated with indwelling medical devices. Headquartered in Denver, Colorado, Ceragenix Pharmaceuticals, Inc. was launched as a public company in 2005 after completing the acquisition of Osmotics Pharma, Inc. The Company has maintained a lean infrastructure, leveraging contract research partners and academic labs for initial proof of concept studies.
Chief Executive Officer, Chairman and Director
Steven PorterPeer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Ceragenix Pharmaceuticals, Inc. (CGXP.OB) and Megapharm Enter Into Distribution and Supply Agreement for EpiCeram
-
Ceragenix and Nobel Biocare Enter into Option to License Agreement for Antimicrobial Technology
News & Analysis
Filter by
ceragenix pharmaceuticals inc. - All News and Analysis
Ceragenix™ Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
Testing Performed at the University of Pennsylvania's Institute of Medicine and Engineering DENVER -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that researchers at the University of Pennsylvania led by Dr. Paul Janmey and Dr. Robert Bucki, in collaboration with Dr....
Morning Updates for Tuesday, September 5, 2006 - Featuring: Tally-Ho Ventures, International Isotopes, FEC Resources, Ceragenix Phamaceuticals, and More.
M2 PRESSWIRE-5 September 2006-Stockguru.com: Morning Updates for Tuesday, September 5, 2006 - Featuring: Tally-Ho Ventures, International Isotopes, FEC Resources, Ceragenix Phamaceuticals, and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:05092006 Dallas, Texas - StockGuru Pre-Market Updates for Tuesday include Tally-Ho Ventures, Inc. (OTCBB:...
Ceragenix To Talk Biopharmaceuticals on MN1.
M2 PRESSWIRE-1 September 2006-MN1.com: Ceragenix To Talk Biopharmaceuticals on MN1C1994-2006 M2 COMMUNICATIONS LTD RDATE:01092006 DALLAS - Steven Porter, chairman and CEO of Ceragenix (OTCBB: CGXP) will be featured live on Market News First (www.mn1.com) for an exclusive interview with the MN1...
Ceragenix To Talk Biopharmaceuticals on MN1.
M2 PRESSWIRE-29 August 2006-MN1.com: Ceragenix To Talk Biopharmaceuticals on MN1C1994-2006 M2 COMMUNICATIONS LTD RDATE:29082006 DALLAS, TX. - Steven Porter, chairman and CEO of Ceragenix (OTCBB: CGXP) will be featured live on Market News First (www.mn1.com) for an exclusive interview with the...
Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 Presenter Profiles
MONTE CARLO, Monaco -- Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 takes place May 15-16 in Monte Carlo. For in-depth information about the event visit http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf9. Below are profiles from Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 presenters; breaking news releases are available at...
Ceragenix Pharmaceuticals Appoints Dr. Donald Leung to its Scientific Advisory Board
DENVER -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has appointed Donald Leung, M.D., Ph.D., to its Scientific Advisory Board. Donald Y. M. Leung is a Professor and Head of Pediatric Allergy-Immunology at The National Jewish Medical and Research...
Centers for Disease Control and Prevention and Ceragenix Enter into a Cooperative Research and Development Agreement
DENVER -- CRADA to Evaluate the Efficacy of Ceragenix's CeracideTM Antimicrobial Coating in the Prevention of Bacterial Biofilm Growth on Medical Devices Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the "Company"), a development stage biopharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Jeff Sperber | Director, Chief Financial Officer |
| Peter Elias | Chief Scientific Officer |
| Carl Genberg | Senior Vice President |
| Russell L. Allen | Vice President of Corporate Development |
| Donald Y M Leung | Professor and Head of Pediatric |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Steven Porter | Chief Executive Officer, Chairman and Director |
| Cheryl A. Hoffman-Bray | Director and Chair of Audit Committee |
| Philippe J. Gastone | Director and Chair of Compensation Committee |
| Michael S Niederman | Prof of Medicine and Chairman of The Department of Medicine at The State University of New York |
| Sean P Gorman | Head of School and Chair |
| Alberto J Bautista | Board of Directors |
| Henry F Chambers | Board of Directors |
| Michael J Rybak | Board of Directors |
| Michel Darnaud | Board of Directors |
| Richard Gallo | Board of Directors |
| Tomas Ganz | Board of Directors |
Steven S. Porter has served as the Company s Chief Executive Officer and Chairman since May 2005. Prior to joining us, he served as Chief Executive Officer and Chairman of the Board of Osmotics from its inception in August 1993 until May 2005. He served as a director of Osmotics Corporation through December 2007. He has served as Chief Executive Officer and Chairman of Ceragenix Corporation since February 2002. In January 1986, Mr. Porter and two other individuals founded GDP Technologies, Inc. (GDP), a medical imaging company, completing major strategic partnerships with Olympus Optical, Japan, GE Medical and Bruel & Kjaer, Denmark. From that time until August 1993, Mr. Porter served as Executive Vice President of GDP. Prior to 1986, Mr. Porter was the National Sales Manager for Protronyx Research, Inc., a large scale scientific computer systems company, working with the United States Department of Energy, United States Department of Defense, Boeing and the National Security Agency. Mr. Porter has a Bachelor of Arts degree in Economics from UCLA.
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Chief Executive Officer, Chairman and Director | Current |
| Osmotics Corporation | Chief Executive Officer | Former |
| Osmotics Corporation | Chairman of the Board | Former |
| Osmotics Corporation | Director | Former |
| University of California, Los Angeles | Bachelor of Arts Degree In Economics | Former |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Director, Chief Financial Officer | Current |
| Osmotics Corporation | Chief Financial Officer | Former |
| Telecommunications Ltd | Business Unit Controller | Former |
Dr. Peter Elias has served as Chief Scientific Officer since May 2005. Dr. Elias has served as Ceragenix Corporation s Chief Scientific Officer since May 2004. From 1975 through 2003, Dr. Elias was a Professor of Dermatology at the University of California, San Francisco where he most recently served as the Vice Chairman of the Department of Dermatology. Between his tenure at the University of California and joining Ceragenix Corporation, Dr. Elias worked as an independent consultant and advisor. Dr. Elias has published over 500 papers and has received numerous honors, awards and professional appointments as a result of his expertise in the field of dermatology. Dr. Elias received his B.A. from Stanford University and his M.D. and M.S. from the University of California, San Francisco.
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Chief Scientific Officer | Current |
| Osmotics Corporation | Current | |
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| California Academy of Sciences | Fellow | Current |
| University of California | Advisor | Former |
| University of California, San Francisco | Professor | Former |
| Veterans Administration Medical Center | Former | |
| University of California, San Francisco | Chairman | Former |
| University of California, San Francisco | Vice-Chairman | Former |
| University of California, San Francisco | M.D. | Former |
| Stanford University | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Senior Vice President | Current |
| Ceragenix Pharmaceuticals, Inc. | President | Former |
| Osmotics Corporation | Senior Vice President, Research and Development | Former |
| The Ohio State University College of Law | Juris Doctorate Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Ibex Technologies | Vice President | Current |
| Ceragenix Pharmaceuticals, Inc. | Vice President of Corporate Development | Current |
| Ibex Technologies | Board of Directors | Current |
| Amherst College | B.A. | Former |
Cheryl A. Hoffman-Bray was elected as a director of the Company in June 2005. Since August 2006, Ms. Hoffman-Bray has served as the Chief Financial Officer of the Education Development Center, Inc., a non-profit organization that manages projects addressing world wide education and health care needs. From October 2004 through March 2006, she served as the Senior Advisor to the Executive Dean of Harvard University. She served as the Dean of Finance and Chief Financial Officer of Harvard s Faculty of Arts and Sciences from March 2000 until October 2004. Ms. Hoffman Bray served as Chief Financial Officer and Senior Vice President of Finance at the Beth Israel Deaconess Medical Center from May 1998 to May 1999. From October 1996 until May 1998, she served as the Medical Center s Vice President of Finance. From January 1995 to October 1996, Ms. Hoffman Bray served as the Senior Vice President and Chief Financial Officer of the New England Deaconess Hospital in Boston, Massachusetts. From June 1984 to December 1994, she worked for Albany Memorial Health Systems, Inc., serving as their Vice President and Chief Financial Officer from July 1989 until December 1994 and as the Controller and Director of Fiscal Services from June 1984 until July 1989. From 1980 until May 1984, she was employed by Coopers & Lybrand. Ms. Hoffman Bray graduated from the State University of New York at Albany 1979 with a Bachelor of Science in Accounting and received her Master of Science from the University in 1980. Ms. Hoffman Bray is a member of the Boston Club and a director of the Harvard Cooperative Society.
| Organization | Position | Status |
|---|---|---|
| Education Development Center Inc. | Chief Financial Officer | Current |
| Ceragenix Pharmaceuticals, Inc. | Director and Chair of Audit Committee | Current |
| Harvard University | Senior Advisor | Current |
| The Boston Club | Board of Directors | Current |
| Ceragenix Pharmaceuticals, Inc. | Director | Current |
| Harvard Cooperative Society Inc. | Director | Current |
| The Boston Club | Member | Current |
| Beth Israel Deaconess Medical Center | Chief Financial Officer | Former |
| New England Deaconess Hospital | Senior Vice President and Chief Financial Officer | Former |
| Beth Israel Deaconess Medical Center | Senior Vice President of Finance | Former |
| University Corp. | Master of Science | Former |
| The State University of New York | Bachelor of Science | Former |
| State University of New York at Albany | Bachelor of Science In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Huttig Building Products, Inc. | Senior Vice President, Cemex | Current |
| Ceragenix Pharmaceuticals, Inc. | Director and Chair of Compensation Committee | Current |
| Timber Treatment Technologies, LLC | Current | |
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Huttig Building Products, Inc. | Director | Current |
| Cemex, Inc. | Senior Vice President | Former |
| Booz Allen Hamilton, Inc. | Former | |
| The Boston Consulting Group, Inc. | Former | |
| INSEAD | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Professor and Head of Pediatric | Current |
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Prof of Medicine and Chairman of The Department of Medicine at The State University of New York | Current |
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Head of School and Chair | Current |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Ajb Consulting Ltd | Founder | Former |
| MIT Sloan School of Management | M.S. In Management | Former |
| Ajb Consulting Ltd | Principal Consultant | Former |
| University Corp. | M.S. In Management | Former |
| MIT Sloan School of Management | M.S. In Management | Former |
| University Corp. | B.S. In Industrial Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Baxter International Inc. | Former | |
| Diagnostica Stago, Inc. | General Manager | Former |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Ceragenix Pharmaceuticals, Inc. | Board of Directors | Current |
Executive News
-
Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield(TM)...
-
Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield Antimicrobial Coating Application
-
Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield„ Antimicrobial Coating Application
-
Ceragenix Completes Long-Term Antimicrobial Efficacy Test on Treated Silicone Medical Device
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes


